Reference:
Rosenberg, E. S., Dorabawila, V., Easton, D., Bauer, U. E., Kumar, J., Hoen, R., Hoefer, D., Wu, M., Lutterloh, E., Conroy, M. B., Greene, D., & Zucker, H. A. (2022). Covid-19
Vaccine Effectiveness in New York State. The New England Journal of Medicine, 386(2), 116-127. https://doi.org/10.1056/NEJMoa2116063
Summary:
This study evaluates the effectiveness of three Covid-19 vaccines—BNT162b2, mRNA-1273, and Ad26.COV2.S—among New York State adults from May to August 2021. Analysis of data from over 8.6 million adults revealed that vaccine effectiveness declined significantly as the delta variant became predominant. Initially, the effectiveness was high, with BNT162b2 at 91.3% and mRNA-1273 at 96.9%, but dropped to 74.2% by August. Hospitalisation rates remained high among vaccinated individuals, particularly in the 65+ age group. Despite declines, effectiveness against severe disease largely persisted, highlighting the need for booster vaccinations, especially for older adults.